COVID-19 and Simulations Plus

Viral Kinetics App

Epidemiology App

Viral Kinetics App

Epidemiology App

SimulationsPlus can help you respond to COVID-19

Solving the global COVID-19 pandemic will require innovative and integrative new approaches to accelerate drug development.

From lead discovery to re-purposing of promising existing therapies, to predicting whole-body and target tissue drug exposure, to understanding interactions between treatment and disease in both the acute and chronic setting, to de-risking clinical trials and maximizing patient benefit, Simulations Plus has the tools and expertise to move your COVID-19 drug development program forward. Watch this video to learn what our divisional Presidents have committed to fighting the COVID-19 pandemic.

 


Sandra Suarez-Sharp, Ph.D.
Vice President, Regulatory Affairs
Simulations Plus, Inc.

Kevin Dykstra, Ph.D.
Vice President, Consulting Services
Cognigen, a Simulations Plus Company

Hover over the elements for more information.